Print this page    •   Back to Web version of article

Structured Treatment Interruptions Workshop Summary

January 31, 2001

Designing Trials to Demonstrate Immune Benefit from STI

The aggregate of experience from many small studies, anecdotal reports and observational databases provides what we know so far about the safety of STI. Despite this experience, reproducible HIV-1-specific immune control has not yet been demonstrated.

The number of variables that must be considered when designing trials to evaluate potential immune benefits are daunting: The duration of a scheduled interruption may be determined by:

(CD4+ or RNA triggers can be defined as absolute numbers or as relative changes from a setpoint.)

The choice of number and duration of subsequent interruptions multiplies the variables:

The duration of treatment after interruption is another consideration:

Hypotheses exist to support each of these approaches, and evidence from animal models can be used to argue for one or another. Short of hitting on a lucky combination in another round of small trials, much basic science and animal research may be needed before interruption schedules for large Phase III trials can be confidently selected. Appendix 2


Previous | Next
Table of Contents




This article was provided by Project Inform. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art5268.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.